Company news

Oncolytics Biotech Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

August 5, 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

July 29, 2025

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

July 29, 2025

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 23, 2025

High?Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

July 23, 2025

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

July 22, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

July 16, 2025

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

July 16, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

July 10, 2025

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

July 10, 2025

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

July 8, 2025

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 8, 2025

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

June 30, 2025

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

June 30, 2025

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

June 26, 2025

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

June 18, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

June 12, 2025

After Major Oncology Conference, All Eyes Turn to Industry Innovation

June 12, 2025

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

May 23, 2025

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

May 1, 2025

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

April 24, 2025

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 10, 2025

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

April 10, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

March 8, 2025

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

March 7, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

February 27, 2025

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

February 25, 2025

Investors Eye Biotech Sector as Cancer Therapy Market Surges

February 19, 2025

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

February 19, 2025

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

February 19, 2025

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

February 18, 2025

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

February 13, 2025

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

February 6, 2025

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

January 22, 2025

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

December 2, 2024

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

November 11, 2024

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

October 3, 2024

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

September 18, 2024

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

July 31, 2024

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

June 26, 2024

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

June 23, 2024

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

June 19, 2024

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 23, 2024

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 14, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.